Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001018

Cisplatin impurity A

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

trans-Platinum(II)diammine dichloride, trans-Diamminedichloroplatinum(II), trans-Dichlorodiammineplatinum(II)

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
Pt(NH3)2Cl2
Numéro CAS:
14913-33-8
Poids moléculaire :
300.05
Numéro MDL:
MFCD00011623
Code UNSPSC :
41116107
ID de substance PubChem :
329831221
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

cisplatin

Fabricant/nom de marque

EDQM

Pf

340 °C (dec.) (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

Clé InChI

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cisplatin impurity A EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

C2210000

Cisplatin, European Pharmacopoeia (EP) Reference Standard

Y0001019

Cisplatin impurity B, European Pharmacopoeia (EP) Reference Standard

1551300

Potassium Trichloroammineplatinate, United States Pharmacopeia (USP) Reference Standard

1672803

Transplatin, United States Pharmacopeia (USP) Reference Standard

1134357

Cisplatin, United States Pharmacopeia (USP) Reference Standard

PHR1624

Cisplatin, Pharmaceutical Secondary Standard; Certified Reference Material

BP809

Cisplatin, British Pharmacopoeia (BP) Reference Standard

BP510

Potassium trichloroammineplatinate, British Pharmacopoeia (BP) Reference Standard

BP544

Transplatin, British Pharmacopoeia (BP) Reference Standard

PHR3252

Transplatin, pharmaceutical secondary standard, certified reference material

Pictogrammes

Health hazardCorrosion
GHS08,GHS05

Mention d'avertissement

Danger

Mentions de danger

H317,H318,H334

Classification des risques

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

vibrant-m

Y0000275

Dichlorodiaminocyclohexaneplatinum

Cisplatin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1624

Cisplatin

cis-Diammineplatinum(II) dichloride crystalline

Sigma-Aldrich

P4394

cis-Diammineplatinum(II) dichloride

James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
Xi-Chun Hu et al.
The Lancet. Oncology, 16(4), 436-446 (2015-03-22)
Platinum chemotherapy has a role in the treatment of metastatic triple-negative breast cancer but its full potential has probably not yet been reached. We assessed whether a cisplatin plus gemcitabine regimen was non-inferior to or superior to paclitaxel plus gemcitabine
Koichi Azuma et al.
Oncotarget, 5(15), 5908-5919 (2014-08-15)
Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to
Yuniardini S Wimardhani et al.
Journal of oral science, 56(2), 119-126 (2014-06-17)
Chitosan, a multipurpose biomaterial, has been shown to exert effects against several types of cancer including oral cancer. However, the mechanisms underlying the anticancer activities of chitosan on oral squamous cell carcinoma (SCC) cells remain largely unknown. The present study
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique